导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.32% | 3235/4773 |
| 近一周 | -2.17% | 1379/5462 |
| 近一月 | -4.48% | 2503/5421 |
| 近一季 | -8.98% | 3051/5209 |
| 近半年 | -5.19% | 2774/4920 |
| 近一年 | -2.53% | 3017/4366 |
| 近两年 | 38.60% | 1955/2954 |
| 近三年 | 26.01% | 1235/2253 |
| 成立以来 | 73.55% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.20% 2715/4961 |
9.79% 2464/5312 |
- - |
- - |
| 2025 | 21.50% 2032/4813 |
2.47% 1361/3635 |
2.50% 1530/4076 |
15.27% 2825/4524 |
0.35% 2050/4813 |
| 2024 | 17.69% 659/3463 |
2.98% 644/2808 |
2.51% 345/3014 |
14.43% 1974/3129 |
-2.57% 2137/3463 |
| 2023 | -6.56% 859/2656 |
7.43% 577/2280 |
-3.55% 831/2385 |
-2.70% 725/2515 |
-7.31% 2115/2655 |
| 2022 | -20.64% 988/2207 |
-10.74% 417/1919 |
4.10% 1058/2016 |
-12.12% 648/2113 |
-2.81% 1816/2208 |
| 2021 | 1.16% 687/1822 |
-0.70% 384/1255 |
11.05% 404/1330 |
-6.74% 985/1466 |
-1.63% 1379/1822 |
| 2020 | 46.93% 201/1250 |
-2.64% 269/1028 |
15.12% 516/1067 |
14.41% 278/1164 |
14.59% 264/1184 |
| 2019 | 30.07% 489/1092 |
16.73% 667/739 |
-0.77% 281/788 |
2.72% 288/850 |
9.32% 233/918 |
| 2018 | - - |
- - |
- - |
-2.12% 279/660 |
-10.79% 227/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 长信沪深300指数增强A VS. 长安沪深300非周期A(740101) |